特发性膜性肾病的分子发病机制

doi:10.3877/cma.j.issn.2095-3216.2015.06.008

特发性膜性肾病( IMN)是国内外常见的引起成人肾病综合征的病理类型之一。在中国人群中，近年来特发性膜性肾病在原发性肾小球疾病中所占比例明显升高。由于病因及发病机制仍不清楚，以及缺乏预测疾病活动性的生物学标志物，因此目前治疗所带来的经济负担以及药物毒性仍具有争议和挑战。IMN是一种器官特异性的自身免疫性疾病，非炎症性自身抗体与足细胞上的靶抗原结合，在基底膜外侧上皮下形成原位免疫复合物，激活补体，从而引起足细胞损伤和蛋白尿。Heymann肾炎模型是经典的膜性肾病动物模型，然而其靶抗原Megalin并不是人类膜性肾病发生的原因。之后，中性肽链内切酶(NEP)被证实为母胎同种异体产前膜性肾病的靶抗原。直到2009年，磷脂酶A2受体(PLA2R)被证实为IMN的靶抗原。在IMN患者血浆中检测到抗PLA2R-IgG4，其特异性高达100%，敏感性约为70%～80%。抗PLA2R-IgG4滴度可以预测疾病的活动性，其与PLA2R抗原结合形成原位免疫复合物，激活补体凝集素途径，形成C5b-9膜攻击复合物沉积在足细胞上，引起足细胞损伤，导致蛋白尿形成。HLA-DQA1与PLA2R基因多态性均与IMN的发病相关，二者的风险基因具有叠加效应。综上所述，IMN的发生是多种因素共同作用的结果，包括易感基因、靶抗原、自身抗体、补体等，这些研究进展对于IMN的诊断和治疗具有重要意义。

关键词: 特发性膜性肾病, 动物模型, 足细胞, 磷脂酶A2受体, 人类白细胞抗原-DQA1

Idiopathic membranous nephropathy (IMN) is one of the common pathological types of adult nephrotic syndrome in the world. In China, the proportion of IMN among primary glomerular diseases increased obviously in recent years. Because the etiology and the pathogenesis of IMN are not well-known, and there is a lack of biomarkers for predicting activity of IMN, the economic burden and drugs toxicity caused by the treatment remain to be controversial and challenging. IMN is an organ-specific autoimmune disease, in which non-inflammatory autoantibodies can bind target antigens on podocytes, forming subepithelial in-situ immunocomplex on the outside of the glomerular basement membrane that provokes local complement activation so as to cause podocyte injury and proteinuria. The Heymann nephritis model is a classical animal model for MN. However, megalin, which was the target antigen of this model, was not the cause of human IMN. Then, neutral endopeptidase (NEP) was found to be the target antigen of maternal-fetal alloimmunization with antenatal MN. To 2009, phospholipase A2 receptor (PLA2R) was confirmed as the target antigen of IMN. Anti-PLA2R-IgG4 was detected in serum with high specificity of 100% and sensitivity of 70%-80% in IMN patients. Anti-PLA2R-IgG4 could bind PLA2R antigen. Complement lectin pathway was activated by these in-situ immune complex and C5b-9 was generated. C5b-9 membrane attack complex could cause podocytes injury and production of proteinuria. In addition, the level of anti-PLA2R antibodies can predict the activity of the disease. HLA-DQA1 and PLA2R loci are associated with the onset of IMN, and the risk allels of both genes have additive effects. All in all, many factors are involved in the onset of IMN, such as genetic predisposition, target antigens, autoantibodies and complement, etc. These findings are of great significance for the diagnosis and treatment of IMN .

Key words: Idiopathic membranous nephropathy, Animal model, Podocyte, PLA2R, HLA-DQA1

图1 磷脂酶A2受体相关特发性膜性肾病的发病机制

1	Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy: an update [J]. Semin Immunopathol, 2014, 36(4): 381-397.
2	Zhu P, Zhou FD, Wang SX, et al. Increasing frequency of idiopathic membranous nephropathy in primary glomerular disease: A 10-year renal biopsy study from a single Chinese nephrology centre [J]. Nephrology (Carlton), 2015, 20(8): 560-566.
3	Polanco N, Gutierrez E, Rivera F, et al. Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment [J]. Nephrol Dial Transplant, 2012, 27(1): 231-234.
4	Polanco N, Gutierrez E, Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy [J]. J Am Soc Nephrol, 2010, 21(4): 697-704.
5	Glassock RJ. Diagnosis and natural course of membranous nephropathy [J]. Semin Nephrol, 2003, 23(4): 324-332.
6	Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy [J]. Nat Rev Nephrol, 2013, 9(8): 443-458.
7	Waldman M, Austin HR. Controversies in the treatment of idiopathic membranous nephropathy [J]. Nat Rev Nephrol, 2009, 5(8): 469-479.
8	Beck LJ, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1): 11-21.
9	Kanigicherla D, Gummadova J, Mckenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy [J]. Kidney Int, 2013, 83(5): 940-948.
10	Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy [J]. N Engl J Med, 2011, 364(7): 616-626.
11	Heymann W, Hackel DB, Harwood S, et al. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions [J]. Proc Soc Exp Biol Med, 1959, 100(4): 660-664.
12	Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border [J]. Proc Natl Acad Sci USA, 1982, 79(18): 5557-5561.
13	Prabakaran T, Nielsen R, Larsen JV, et al. Receptor-mediated endocytosis of alpha-galactosidase A in human podocytes in Fabry disease [J]. PLoS One, 2011, 6(9): e25065.
14	Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care [J]. Lancet, 2015, 385(9981): 1983-1992.
15	Border WA, Ward HJ, Kamil ES, et al. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen [J]. J Clin Invest, 1982, 69(2): 451-461.
16	Adler SG, Wang H, Ward HJ, et al. Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit [J]. J Clin Invest, 1983, 71(3): 487-499.
17	Zhang JJ, Malekpour M, Luo W, et al. Murine membranous nephropathy: immunization with alpha3 (IV) collagen fragment induces subepithelial immune complexes and Fc gamma R-independent nephrotic syndrome [J]. J Immunol, 2012, 188(7): 3268-3277.
18	Jia XY, Hu SY, Chen JL, et al. The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy [J]. Kidney Int, 2014, 85(4): 945-952.
19	Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies [J]. N Engl J Med, 2002, 346(26): 2053-2060.
20	Ronco P, Debiec H, Guigonis V. Mechanisms of disease: Alloimmunization in renal diseases [J]. Nat Clin Pract Nephrol, 2006, 2(7): 388-397.
21	Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies [J]. Lancet, 2004, 364(9441): 1252-1259.
22	Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization [J]. J Am Soc Nephrol, 2005, 16(5): 1205-1213.
23	Vivarelli M, Emma F, Pelle T, et al. Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies [J]. Kidney Int, 2015, 87(3): 602-609.
24	Nortier JL, Debiec H, Tournay Y, et al. Neonatal disease in neutral endopeptidase alloimmunization: lessons for immunological monitoring [J]. Pediatr Nephrol, 2006, 21(10): 1399-1405.
25	Ancian P, Lambeau G, Mattei MG, et al. The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization [J]. J Biol Chem, 1995, 270(15): 8963-8970.
26	Beck LJ, Salant DJ. Membranous nephropathy: from models to man [J]. J Clin Invest, 2014, 124(6): 2307-2314.
27	Pan Y, Wan J, Liu Y, et al. sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor [J]. Sci Rep, 2014, 4: 6660.
28	Augert A, Payre C, de Launoit Y, et al. The M-type receptor PLA2R regulates senescence through the p53 pathway [J]. EMBO Rep, 2009, 10(3): 271-277.
29	Sis B, Tasanarong A, Khoshjou F, et al. Accelerated expression of senescence associated cell cycle inhibitor p16INK4A in kidneys with glomerular disease [J]. Kidney Int, 2007, 71(3): 218-226.
30	Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy [J]. J Am Soc Nephrol, 2012, 23(10): 1735-1743.
31	Zvaritch E, Lambeau G, Lazdunski M. Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2 [J]. J Biol Chem, 1996, 271(1): 250-257.
32	Kao L, Lam V, Waldman M, et al. Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy [J]. J Am Soc Nephrol, 2015, 26(2): 291-301.
33	Fresquet M, Jowitt TA, Gummadova J, et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy [J]. J Am Soc Nephrol, 2015, 26(2): 302-313.
34	Seitz－Polski B, Dolla G, Payre C, et al. Epitope Spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy [J]. J Am Soc Nephrol, 2015, Epub ahead of print.
35	Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin [J]. N Engl J Med, 2011, 364(22): 2101-2110.
36	Sathe SK, Teuber SS, Roux KH. Effects of food processing on the stability of food allergens [J]. Biotechnol Adv, 2005, 23(6): 423-429.
37	van Elburg RM, Fetter WP, Bunkers CM, et al. Intestinal permeability in relation to birth weight and gestational and postnatal age [J]. Arch Dis Child Fetal Neonatal Ed, 2003, 88(1): F52-F55.
38	Tomas NM, Beck LJ, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy [J]. N Engl J Med, 2014, 371(24): 2277-2287.
39	Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2 [J]. J Am Soc Nephrol, 2010, 21(3): 507-519.
40	Vivarelli M, Emma F, Pelle T, et al. Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies [J]. Kidney Int, 2015, 87(3): 602-609.
41	van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies [J]. Clin Exp Immunol, 1986, 64(2): 415-422.
42	Aalberse RC, Schuurman J. IgG4 breaking the rules [J]. Immunology, 2002, 105(1): 9-19.
43	Huang CC, Lehman A, Albawardi A, et al. IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression [J]. Mod Pathol. 2013, 26(6): 799-805.
44	Lhotta K, Wurzner R, Konig P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis [J]. Nephrol Dial Transplant, 1999, 14(4): 881-886.
45	Espinosa-Hernandez M, Ortega-Salas R, Lopez-Andreu M, et al. C4d as a diagnostic tool in membranous nephropathy [J]. Nefrologia, 2012, 32(3): 295-299.
46	Malhotra R, Wormald MR, Rudd PM, et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein [J]. Nat Med, 1995, 1(3): 237-243.
47	Kerjaschki D. Pathomechanisms and molecular basis of membranous glomerulopathy [J]. Lancet, 2004, 364(9441): 1194-1196.
48	Vangelista A, Tazzari R, Bonomini V. Idiopathic membranous nephropathy in 2 twin brothers [J]. Nephron, 1988, 50(1): 79-80.
49	Bockenhauer D, Debiec H, Sebire N, et al. Familial membranous nephropathy: an X-linked genetic susceptibility [J] ? Nephron Clin Pract, 2008, 108(1): c10-c15.
50	Chen JS, Chen A, Chang LC, et al. Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences [J]. Nephrol Dial Transplant, 2004, 19(11): 2721-2728.
51	Bagchus WM, Hoedemaeker PJ, Vos JT, et al. Thymocytes reacting with heterologous antibodies against GP 330 in autologous immune complex glomerulopathy (AICG) in the rat. The relation between susceptibility for AICG and anti-GP 330-binding thymocytes [J]. Immunobiology, 1989, 179(4-5): 432-444.
52	Klouda PT, Manos J, Acheson EJ, et al. Strong association between idiopathic membranous nephropathy and HLA-DRW3 [J]. Lancet, 1979, 2(8146): 770-771.
53	Papiha SS, Pareek SK, Rodger RS, et al. HLA-A, B, DR and Bf allotypes in patients with idiopathic membranous nephropathy (IMN) [J]. Kidney Int, 1987, 31(1): 130-134.
54	Hiki Y, Kobayashi Y, Itoh I, et al. Strong association of HLA-DR2 and MT1 with idiopathic membranous nephropathy in Japan [J]. Kidney Int, 1984, 25(6): 953-957.
55	Lv J, Hou W, Zhou X, et al. Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy [J]. J Am Soc Nephrol, 2013, 24(8): 1323-1329.
56	Kanigicherla D, Gummadova J, Mckenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy [J]. Kidney Int, 2013, 83(5): 940-948.
57	Bullich G, Ballarin J, Oliver A, et al. HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy [J]. Clin J Am Soc Nephrol, 2014, 9(2): 335-343.
58	Coenen MJ, Hofstra JM, Debiec H, et al. Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy [J]. J Am Soc Nephrol, 2013, 24(4): 677-683.

[1]	黄钰清, 武杜杜, 潘菲, 王俊康, 钟兆明, 黎檀实, 吕发勤. 掌上超声在枪弹伤致髂动脉破裂大出血建模中的应用研究[J]. 中华医学超声杂志（电子版）, 2022, 19(10): 1112-1117.
[2]	李传举, 刘林月, 王美, 李昕, 韩祥辉, 贾海永. 乙型肝炎病毒感染模型研究进展[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(06): 361-365.
[3]	邵世锋, 伍正彬, 段朝霞, 张良潮, 王耀丽, 李琦, 王建民. 山羊高原重度原发性肺冲击伤模型的建立[J]. 中华肺部疾病杂志(电子版), 2022, 15(05): 637-642.
[4]	邵世锋, 程祥云, 李琦, 曾琳, 张良潮, 雷洋, 伍正彬, 段朝霞, 王耀丽, 王建民. 山羊重度原发性肺冲击伤模型的建立[J]. 中华肺部疾病杂志(电子版), 2021, 14(06): 723-728.
[5]	王琴, 陈怡, 白冲, 王湘奇, 孙春燕. 自制动物模型存放盒的设计及应用评价[J]. 中华肺部疾病杂志(电子版), 2021, 14(04): 547-548.
[6]	李青霖, 宋仁杰, 周飞虎. 一种重型劳力性热射病相关急性肾损伤小鼠模型的建立与探讨[J]. 中华肾病研究电子杂志, 2023, 12(05): 265-270.
[7]	辛洋洋, 王兴智. 神经表皮生长因子样蛋白1在膜性肾病中的研究进展[J]. 中华肾病研究电子杂志, 2022, 11(05): 290-293.
[8]	王晓玉, 胡豪飞, 韦宁荣, 毕慧欣. 特发性膜性肾病患者血清β2微球蛋白与局灶节段性肾小球硬化病变的关系分析[J]. 中华肾病研究电子杂志, 2022, 11(05): 249-257.
[9]	梁小雨, 米杰. 磷脂酶A2受体相关特发性膜性肾病研究进展[J]. 中华肾病研究电子杂志, 2022, 11(01): 52-56.
[10]	姜金玉, 张东蕾, 何伟. 蓝光照射氧化损伤模型在眼部疾病中应用的研究进展[J]. 中华眼科医学杂志(电子版), 2022, 12(03): 168-172.
[11]	路明, 杨博, 刘扬, 王慧, 洪文, 黄克林, 刘青. 肛门失禁大动物模型的建立[J]. 中华临床医师杂志(电子版), 2022, 16(04): 356-361.
[12]	郭俏丽, 胡慧. 人源性肿瘤异种移植模型在三阴性乳腺癌研究中的应用[J]. 中华临床医师杂志(电子版), 2021, 15(10): 790-793.
[13]	邹杰锋, 许云鹏, 张燕子, 隋晓露, 袁树珍, 曾启城, 李丽香, 谢婷妃, 徐子斌, 陈继红. JAK₂/STAT₃信号通路在局灶节段性肾小球硬化足细胞损伤中的作用及机制[J]. 中华临床医师杂志(电子版), 2021, 15(09): 683-690.
[14]	李世凯, 梁佳, 何艳艳, 于毅, 李天晓, 常金龙, 贺迎坤. 兔颈动脉粥样硬化性狭窄模型在介入治疗的应用进展[J]. 中华介入放射学电子杂志, 2023, 11(04): 357-362.
[15]	高飞, 李惠凯, 冯秀雪, 杜晨, 韩珂, 柴宁莉, 令狐恩强. 3%聚桂醇消融动物囊性肿瘤模型的有效性和安全性研究[J]. 中华胃肠内镜电子杂志, 2023, 10(01): 31-36.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

The molecular pathogenesis of idiopathic membranous nephropathy

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

The molecular pathogenesis of idiopathic membranous nephropathy